445 related articles for article (PubMed ID: 33507515)
61. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.
Yatabe Y; Suzuki R; Tobinai K; Matsuno Y; Ichinohasama R; Okamoto M; Yamaguchi M; Tamaru J; Uike N; Hashimoto Y; Morishima Y; Suchi T; Seto M; Nakamura S
Blood; 2000 Apr; 95(7):2253-61. PubMed ID: 10733493
[TBL] [Abstract][Full Text] [Related]
62. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
Sarkozy C; Ribrag V
Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
[TBL] [Abstract][Full Text] [Related]
63. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
64. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
65. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
[TBL] [Abstract][Full Text] [Related]
66. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.
Pérez-Galán P; Dreyling M; Wiestner A
Blood; 2011 Jan; 117(1):26-38. PubMed ID: 20940415
[TBL] [Abstract][Full Text] [Related]
67. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
68. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.
Raghani NR; Shah DD; Shah TS; Chorawala MR; Patel RB
Crit Rev Oncol Hematol; 2023 Oct; 190():104085. PubMed ID: 37536448
[TBL] [Abstract][Full Text] [Related]
69. Novel agents in mantle cell lymphoma.
Tucker D; Rule S
Expert Rev Anticancer Ther; 2017 Jun; 17(6):491-506. PubMed ID: 28480764
[TBL] [Abstract][Full Text] [Related]
70. Mantle cell lymphoma in relapse: the role of emerging new drugs.
Diefenbach CS; O'Connor OA
Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
[TBL] [Abstract][Full Text] [Related]
71. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.
Morabito F; Recchia AG; Vigna E; Botta C; Skafi M; Abu-Rayyan M; Atrash M; Galimberti S; Morabito L; Al-Janazreh H; Martino M; Cutrona G; Gentile M
Expert Opin Pharmacother; 2020 Jan; 21(1):29-38. PubMed ID: 31738609
[No Abstract] [Full Text] [Related]
72. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.
Jain P; Wang M
Am J Hematol; 2019 Jun; 94(6):710-725. PubMed ID: 30963600
[TBL] [Abstract][Full Text] [Related]
73. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
74. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
[TBL] [Abstract][Full Text] [Related]
75. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
76. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
77. Optimal management of mantle cell lymphoma in the primary setting.
Tang C; Kuruvilla J
Expert Rev Hematol; 2019 Sep; 12(9):715-721. PubMed ID: 31268728
[No Abstract] [Full Text] [Related]
78. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.
Kurita D; Takeuchi K; Kobayashi S; Hojo A; Uchino Y; Sakagami M; Ohtake S; Takahashi H; Miura K; Iriyama N; Sugitani M; Miyoshi H; Hatta Y; Ohshima K; Takei M
Virchows Arch; 2016 Oct; 469(4):471-6. PubMed ID: 27457074
[TBL] [Abstract][Full Text] [Related]
79. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
80. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Jain P; Wang ML
Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
